E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Choroidal neovascularisation (CNV) secondary to pathological myopia (PM) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060823 |
E.1.2 | Term | Choroidal neovascularisation |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067128 |
E.1.2 | Term | Myopic retinal degeneration |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To provide safety and efficacy data in patients with CNV secondary to PM using a guided individualised as-needed (PRN) dosage schedule. The mean change in best-corrected visual acuity (BCVA) from Baseline to Month 12. |
|
E.2.2 | Secondary objectives of the trial |
-mean change in best corrected visual acuity (BCVA) from Baseline to Month 6 - mean change in retinal thickness from baseline to months 6 to 12 - time to the first retreatment and the total number of treatments - change in lesion size and morphology from screening to months 6 and 12 safety of intravitreal injections of ranibizumab (0.5mg) in patients with CNV secondary to PM |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Written informed consent must be obtained before any assessment is performed • Male or female outpatients of any race, aged 18 years or older • Diagnosis of active primary or recurrent subfoveal or juxtafoveal CNV secondary to PM • Diagnosis of high myopia of at least -6 dioptres in the study eye spherical equivalent. For subjects who have undergone prior refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye must have been at least -6 dioptres • Patients who have a BCVA score between 78 and 24 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS)-like grading charts (approximately 6/9 – 6/96 Snellen equivalent) • Patients willing and able to comply with all study procedures
|
|
E.4 | Principal exclusion criteria |
• History of any surgical intervention in the study eye within two months preceding Visit 1 (screening) • Previous macular laser photocoagulation, treatment with intravitreal steroids, verteporfin with photodynamic therapy (Visudyne®) or anti-VEGF agents ranibizumab, bevacizumab or pegaptanib sodium (Macugen®) in the study eye • Previous treatment with intravenously administered bevacizumab (Avastin®) • Prior treatment in the study eye with external-beam radiation therapy, vitrectomy, or transpupillary thermotherapy • Previous participation in any studies of investigational drugs within one month preceding Visit 1 (excluding vitamins and minerals) • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes • History of allergic reaction to fluorescein • Concurrent use of systemic anti-VEGF agents • Current use of or likely need for systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/ hydroxychloroquine (Plaquenil), tamoxifen, phenothiazines and ethambutol • Concomitant use of chronic NSAIDs for more than seven consecutive days or systemic or topical ocular corticosteroids for three or more consecutive days within six months prior to Visit 1. Note that ASA (aspirin) taken as ‘low dose’ up to 100 mg qd for prophylaxis of myocardial infarction and/or stroke is permitted during study • Previous treatment with or participation in a clinical trial (for either eye) involving anti angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate or corticosteroids, etc.) • Patients who present with CNV of causes other than PM e.g. age-related macular degeneration (AMD), presumed ocular histoplasmosis, angioid streaks, multifocal choroiditis or choroidal rupture • Ocular disorders in the study eye that may confound interpretation of study results, including retinal detachment or macular hole (Stage 3 or 4), active intraocular inflammation (grade trace or above) or persistent macular edema due to uveitis or other inflammatory diseases • Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the 12-month study period • Planned or anticipated need for cataract surgery during the 12-month study period • Sub or juxtafoveal laser scar in the study eye • Vitreous haemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye • Presence of retinal pigment epithelial tear involving the macula in the study eye • History of idiopathic or autoimmune-associated uveitis in either eye • Active or suspected ocular, periocular or intraocular infections e.g. conjunctivitis, keratitis, scleritis or endophthalmitis in either eye. • History of glaucoma filtration surgery or corneal surgery • Extracapsular extraction of cataract with phacoemulsification within 2 months preceding Visit 1, or a history of post-operative complications within the last 12 months preceding Visit 1 in the study eye (uveitis, cyclitis etc.) • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation). • Aphakia or absence of the posterior capsule in the study eye. Previous violation of the posterior capsule in the study eye is also excluded unless it occurred as a result of YAG posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation • Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorder • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL) • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. • Fertile males, defined as all males physiologically capable of conceiving offspring UNLESS the patient and his partner agree to comply with acceptable contraception as listed above.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in best corrected visual acuity (BCVA) from baseline to month 12 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 14 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |